OtherClinical Investigations (Human)
PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D. Zlatopolskiy, Bernd Neumaier, Alexander Drzezga and Markus Dietlein
Journal of Nuclear Medicine December 2016, jnumed.116.185538; DOI: https://doi.org/10.2967/jnumed.116.185538
Felix Dietlein
1 University Hospital of Cologne, Germany;
Carsten Kobe
1 University Hospital of Cologne, Germany;
Stephan Neubauer
2 West-German Prostate Center, Germany;
Matthias Schmidt
1 University Hospital of Cologne, Germany;
Simone Stockter
1 University Hospital of Cologne, Germany;
Thomas Fischer
3 University of Cologne, Germany
Klaus Schomäcker
1 University Hospital of Cologne, Germany;
Axel Heidenreich
1 University Hospital of Cologne, Germany;
Boris D. Zlatopolskiy
1 University Hospital of Cologne, Germany;
Bernd Neumaier
1 University Hospital of Cologne, Germany;
Alexander Drzezga
1 University Hospital of Cologne, Germany;
Markus Dietlein
1 University Hospital of Cologne, Germany;

Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D. Zlatopolskiy, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
Journal of Nuclear Medicine Dec 2016, jnumed.116.185538; DOI: 10.2967/jnumed.116.185538
PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D. Zlatopolskiy, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
Journal of Nuclear Medicine Dec 2016, jnumed.116.185538; DOI: 10.2967/jnumed.116.185538
Jump to section
Related Articles
Cited By...
- An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients
- Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)
- Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
- Protocol for 18F-PSMA PET imaging in staging and management of prostate cancer - a retrospective cohort study
- Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to 177Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement
- Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
- Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management
- An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application
- Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer
- Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy
- Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer
- A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
- Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence--A Narrative Review of the Literature
- Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging
- Discovery of 18F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions
- Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging
- Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
- Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence
- Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT
- Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer
- PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al18F2+
- Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment
- PSMA Ligands for PET Imaging of Prostate Cancer